Search

Your search keyword '"Simonneau, Gérald"' showing total 1,289 results

Search Constraints

Start Over You searched for: Author "Simonneau, Gérald" Remove constraint Author: "Simonneau, Gérald"
1,289 results on '"Simonneau, Gérald"'

Search Results

1. Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021

2. Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study

3. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry

5. Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting

8. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study

9. The changing landscape of chronic thromboembolic pulmonary hypertension management

11. Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program

12. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

13. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

14. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

17. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

18. Portopulmonary hypertension in the current era of pulmonary hypertension management

20. Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France

22. Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension (CTEPH) with mixed anatomical lesions: a proof of concept

23. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors

24. Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study

29. The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.

30. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease

31. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study

32. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

33. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study

36. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study

37. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

39. Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

41. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

43. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases: Insights From Pulmonary Arterial Hypertension

47. Chemotherapy-Induced Pulmonary Hypertension: Role of Alkylating Agents

48. Definition and Classification of Pulmonary Hypertension

49. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension

Catalog

Books, media, physical & digital resources